For research use only. Not for therapeutic Use.
Quisovalimab（Cat No.:I042082）is a monoclonal antibody currently under investigation for its potential use in cancer immunotherapy. It targets a specific immune checkpoint receptor called TIGIT (T cell immunoreceptor with Ig and ITIM domains) on immune cells, which helps tumors evade immune surveillance. By blocking TIGIT, quisovalimab aims to enhance the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for various cancers, including non-small cell lung cancer, and is part of the growing field of immuno-oncology therapies targeting immune checkpoint pathways.
| Catalog Number | I042082 |
| CAS Number | 2427667-03-4 |
| Purity | ≥95% |
